| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma (NCT05626829) | Jian Guan | 2022-07-20 |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (NCT05359445) | Immatics Biotechnologies GmbH | 2022-05-19 |
| Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma (NCT05364905) | ARCAGY/ GINECO GROUP | 2022-05-09 |
| Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors (NCT05189054) | Peking University Third Hospital | 2022-05-01 |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma (NCT05043922) | Haihe Biopharma Co., Ltd. | 2021-10-11 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors (NCT05415475) | Chongqing Precision Biotech Co., Ltd | 2021-09-10 |
| Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions (NCT05045040) | Yosuke Uchitomi | 2021-09-06 |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (NCT05002140) | XRad Therapeutics Inc | 2021-08-24 |
| Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse (NCT04784221) | Centre Francois Baclesse | 2021-03-01 |
| Recurrence After Whipple's (RAW) Study (NCT04596865) | University Hospital Plymouth NHS Trust | 2020-10-12 |
| Cabozantinib to Treat Recurrent Liver Cancer Post Transplant (NCT04204850) | University Health Network, Toronto | 2020-08-07 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL (NCT04421560) | Dana-Farber Cancer Institute | 2020-08-01 |
| Deep Learning Model for the Prediction of Post-LT HCC Recurrence (NCT05200195) | European Hepatocellular Cancer Liver Transplant Group | 2020-01-15 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (NCT03941262) | NKGen Biotech, Inc. | 2019-07-15 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (NCT03686124) | Immatics US, Inc. | 2019-05-14 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 (NCT03441100) | Immatics US, Inc. | 2019-05-02 |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling (NCT03760952) | Immatics US, Inc. | 2019-02-26 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer (NCT04326088) | Chang Gung Memorial Hospital | 2018-04-01 |
| Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck (NCT03132038) | UNICANCER | 2017-03-24 |
| SBRT for Extra-cranial Oligorecurrent Tumor (NCT02410187) | Korea Cancer Center Hospital | 2016-03-01 |